Comparing the Efficacy of Cipram® and Its Iranian Generic Citalopram in patients with mixed-anxiety disorder
- Conditions
- Mixed anxiety-depressive disorder.Mental and behavioural disorders
- Registration Number
- IRCT201405127202N8
- Lead Sponsor
- Psychiatry and Psychology Research Center affiliated by Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
All subjects aged between 18 and 55 years who met the criteria for Mixed Anxiety-Depressive Disorder (MADD) based on the DSM-IV and have Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) scores of less than 24.
Exclusion criteria: History of other psychiatric disorders including personality disorders, mental retardation, organic brain syndrome, neurological disorders, unstable medical situations including cardiovascular, hepatic, renal, endocrine or hematological disorders, alcohol or drug dependence, having suicidal idea, pregnancy and lactation, underwent ECT within the previous six months before the initiation of the study, patients on other drugs that could affect depression or anxiety.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anxiety. Timepoint: at baseline, 4 and 8 weeks after starting medication. Method of measurement: using HAM-A scoring systems.;Depression. Timepoint: at baseline, 4 and 8 weeks after starting medication. Method of measurement: using HAM-D scoring systems.
- Secondary Outcome Measures
Name Time Method